^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer
Excerpt:
...- EGFR wild type...
Trial ID:
Source:
Title:
Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study
Published date:
09/12/2023
Excerpt:
Confirmed advanced NSCLC patients who had received anlotinib alone or in combination were enrolled....Stratification analysis showed the PFS of anlotinib plus immunotherapy was significantly longer in male, adenocarcinoma, <=65 years old, patients stage IV, EGFR wild type, with extrathoracic metastasis, performance status scores ≥ 2, the first-line treatment, patients with a history of hypertension and no previous antiangiogenesis than anlotinib monotherapy.
Secondary therapy:
Immunotherapy
DOI:
https://doi.org/10.2147/IJGM.S424777
Source:
Title:
1004P - Efficacy and safety of anlotinib monotherapy or combination therapy as second-line therapy in EGFR-wild-type non-small cell lung cancer (NSCLC) patients
Published date:
09/05/2022
Excerpt:
Anlotinib with or without anti-PD-1/chemotherapy resulted in longer PFS and higher ORR and DCR as second line therapy in EGFR-wild-type advanced NSCLC patients.
Secondary therapy:
PD1 inhibitor; Chemotherapy
Source:
Title:
EP08.02-158 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC
Published date:
07/12/2022
Excerpt:
The median PFS in group A+D was significantly improved compared with group D [4.36m (95%CI: 2.78-5.94) vs 1.64m (95%CI: 1.48-1.80); HR 0.38 (95%CI: 0.22-0.65), p<0.001)]...The combination of anlotinib plus docetaxel improves survival as second-line treatment of EGFR wild-type NSCLC patients in terms of PFS, ORR, DCR, and has a manageable safety profile.
Secondary therapy:
docetaxel
Trial ID:
Source:
Title:
WS08.14 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC
Published date:
07/12/2022
Excerpt:
The median OS was 11.97m (95%CI: 3.08-20.86) in group A+D and 10.85m (95%CI: 5.44-16.26) in group D [HR 0.82 (95%CI: 0.45-1.47), p=0.501)]. For tumor response, ORR were 35.14% vs 9.52% (p=0.007) and DCR were 83.78% vs 54.76% (p=0.006) in group A+D and group D, respectively. We noted treatment-related adverse events (TRAEs) of grade 3 or above occurred in in 12 (30.0%) of 40 pts in group A+D safety population and 8 (18.6%) of 43 pts in group D safety population. The most common grade 3 or worse TRAEs were Leucopenia (15.0% vs 7.0%), Neutropenia (10.0% vs 4.7%) in group A+D and group D, respectively. The combination of anlotinib plus docetaxel improves survival as second-line treatment of EGFR wild-type NSCLC patients in terms of PFS, ORR, DCR, and has a manageable safety profile. It has been proved to be an effective regimen for EGFR wild-type NSCLC patients progressing after first-line platinum-based chemotherapy combined with Immune checkpoint inhibitors.
Trial ID:
